• 1
    Pearson DC, May GR, Fick G, et al. Azathioprine for maintenance of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley and Sons, Ltd, 2003.
  • 2
    Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895902.
  • 3
    Fuentes D, Torrente F, Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 91321.
  • 4
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 5
    Hamdan-Khalil R, Gala J-L, Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol 2005; 69: 5259.
  • 6
    Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 6073.
  • 7
    Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395400.
  • 8
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 9
    Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 1817.
  • 10
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 26.
  • 11
    Barabino A, Torrente F, Ventura A, Cucchiara S, Castro M, Barbera C. Azathioprine in paediatric inflammatory bowel diseases: an Italian multicentre survey. Aliment Pharmacol Ther 2002; 16: 112530.
  • 12
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 13
    Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 14
    Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 10815.
  • 15
    Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999; 28: 3414.
  • 16
    Weinshilboum RM. Thiopurine pharmacogenetics. Clinical and molecular studies of thiopurine methyltransferase. Drug metab Disp 2001; 29: 6015.
  • 17
    Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schiegelow K. Thiopurine methyl transferase activity in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17: 6567.
  • 18
    Kader HA, Wenner WJ, Telega GW, Maller ES, Baldassano RN. Normal Thiopurine methyltransferase levels do not eliminate mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30: 40913.
  • 19
    Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPAC>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14: 77981.
  • 20
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 65162.